ArticleFrontiers in medicine2025
The association of the pan-immune-inflammation value with mortality in patients monitored in the intensive care unit after cardiopulmonary resuscitation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-cardiac arrest syndrome (PCAS) involves rapid and complex inflammatory responses, yet accessible biomarkers to support early prognostication remain limited. The pan-immune-inflammation value (PIV), derived from routine hematologic indices, has shown prognostic relevance in other inflammatory and malignant conditions; however, its utility in PCAS has not been evaluated. Materials and methods: This retrospective observational study included 193 adult patients who achieved return of spontaneous circulation following cardiopulmonary resuscitation. Demographic, clinical, and laboratory variables were recorded, along with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores. PIV, Systemic Immune-Inflammation Index (SII), and Systemic Inflammation Response Index (SIRI) values were calculated on day 1 and day 3 of ICU admission. Statistical analyses included Mann-Whitney U, chi-square tests, Spearman correlation, ROC analysis, and multivariable logistic regression. Results: Of the 193 patients, 85 (44.0%) died within the first 2 days, and 108 (56.0%) survived ≥ 72 h. Non-survivors had significantly higher SOFA and APACHE II scores. PIV was strongly correlated with SII and SIRI; however, neither day 1 nor day 3 PIV values were independently associated with mortality. ROC analysis demonstrated low discriminatory ability for PIV. Conclusion: Although PIV is an inexpensive and readily accessible marker reflecting systemic inflammation, it did not provide independent prognostic information beyond established clinical severity scores in patients with PCAS. Strong correlations with other leukocyte-based inflammatory indices suggest overlapping biological pathways rather than distinct predictive value. Future multicenter studies with protocolized, more frequent early sampling are needed to characterize early inflammatory responses and identify biomarkers that meaningfully contribute to multimodal prognostication. Until such evidence emerges, PIV should be regarded primarily as a descriptive marker rather than a prognostic tool in this setting. Trial registration: This single-center retrospective study was approved by the Uşak University Ethics Committee (Decision No: 461-461-08, Date: 07/11/2024).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.